This week, Primordial Genetics signed a Letter of Intent with a San Diego-based pharmaceutical company (‘Company A’), for a project involving improvement of an enzyme used for manufacturing high-value pharmaceuticals. The costs of the project will be borne by Company A, and successful completion of the project will result in milestone payments to Primordial Genetics that could total $1.7M over the lifetime of the project.

Company A will have the option for two additional projects under the same terms but with adjusted milestone payments, which could total $16.7M per project over the lifetime of the projects. Company A has paid Primordial Genetics a technology access fee and work on the project has begun as of late November, 2015.

This project represents a tremendous opportunity for Primordial Genetics to demonstrate the power and versatility of its Function Generator genetic technology for protein engineering and development of improved enzyme variants.
The name of Company A and the details of the project will be announced at a future date.

0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

Primordial World HQ

3550 General Atomics Court Building 2, Suite 400 San Diego, CA 92121

info@primordialgenetics.com

(858) 366-0770

Pushing the frontiers of Constructive Biology

©2020 Primordial Genetics, Inc.

Contact Us

You have questions and we have answers.

Sending

Log in with your credentials

Forgot your details?